[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Lee HY, Lee DG, Chun K, Lee S, Song SY: Clear cell carcinoma of the pancreas--a case report and review of the literature. Cancer Res Treat; 2009 Sep;41(3):175-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the WHO classification, primary clear cell carcinoma of the pancreas is rare and it is classified as a "miscellaneous" carcinoma.
  • On the abdominal computed tomography (CT), we detected an abdominal mass involving the pancreas tail and liver, and clear cell carcinoma with rhabdoid feature was seen on the histologic evaluation.
  • The tumor cells showed well defined cell membranes, clear cytoplasm and prominent cell boundaries.
  • She was diagnosed with a primary pancreatic clear cell carcinoma with hepatic metastasis and she received palliative gemcitabine chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2008 Sep;21(9):1075-83 [18536653.001]
  • [Cites] JOP. 2007;8(3):330-4 [17495363.001]
  • [Cites] Histopathology. 1998 May;32(5):444-8 [9639120.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):213-9 [9279977.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):183-202 [9279975.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):381-4 [12478490.001]
  • [Cites] Arch Pathol Lab Med. 1989 Feb;113(2):113-4 [2916901.001]
  • [Cites] Acta Pathol Jpn. 1987 Sep;37(9):1521-6 [3687432.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jun;128(6):693-6 [15163226.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(2):140-4 [15127279.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):233-8 [1983826.001]
  • (PMID = 19809568.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2757667
  • [Keywords] NOTNLM ; Clear cell carcinoma / Pancreas / Rhabdoid tumor
  •  go-up   go-down


2. Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, McCluggage CW, Burger PC, Kepner J, Heideman RL, Pediatric Oncology Group: Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol; 2003 Oct;5(4):261-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.
  • For this reason, the Pediatric Oncology Group conducted a Phase 2 trial of IDA for children with recurrent or progressive brain tumors.
  • Patients were stratified by tumor types into 6 categories: stratum 1, low-grade astrocytoma; stratum 2, malignant glioma (glioblastoma multiforme and anaplastic astrocytoma); stratum 3, medulloblastoma; stratum 4, brainstem glioma; stratum 5, ependymoma; and stratum 6, miscellaneous malignant tumors not included in the previous diagnoses.
  • Cycles were repeated at approximately 21-day intervals until patients developed progressive disease or had completed 6 cycles with stable or improved disease.
  • Most patients developed progressive disease; however, in 21 patients with medulloblastoma there was 1 partial response, and 6 patients had stable disease (SD) that in 4 patients lasted more than 20 weeks.
  • Only 1 patient developed reduced cardiac function.
  • The systemic clearance data for IDA and IDOL were nearly identical to those published on patients with leukemia, and the plasma elimination of the IDOL metabolite was substantially longer than that of the parent drug IDA.
  • We conclude from this data and from that in nonhuman primates that it is unlikely that IDA, daunomycin, or other related anthracyclines will be useful for treating primary CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Idarubicin / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565163.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC1920677
  •  go-up   go-down


3. Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ: A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res; 2004 Nov 15;10(22):7583-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol, using the "window" between diagnostic and definitive surgery.
  • EXPERIMENTAL DESIGN: Eligible patients included those with a diagnosis of atypical ductal hyperplasia, ductal carcinoma in situ, lobular carcinoma in situ, or invasive carcinoma (<3 cm in size) that required further surgery.
  • Reasons for nonparticipation included protocol ineligibility, conflict of timing of surgery, miscellaneous logistical reasons, or patient's choice.
  • The power to observe changes in candidate SEB was diminished by a 44% incidence of cases in which the index lesion was not present in the definitive surgical specimen.
  • CONCLUSIONS: Preoperative POH exposure was safe and suitable for a more definitive phase II SEB study.
  • Further investigations must overcome logistical obstacles to accrual, and they must focus on approaches to maximize tissue collection and to incorporate genomic analysis of target lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Breast Neoplasms / drug therapy. Monoterpenes / therapeutic use
  • [MeSH-minor] Aged. Apoptosis. Biomarkers. Biopsy. Carcinoma in Situ. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Cell Proliferation. Cohort Studies. Female. Humans. Immunohistochemistry. Middle Aged. Pilot Projects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15569989.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-65003
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Monoterpenes; 319R5C7293 / perilla alcohol
  •  go-up   go-down


Advertisement
4. Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P: Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Invest New Drugs; 2008 Oct;26(5):407-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
  • The novel agent Irofulven (HMAF, NSC 683863) has demonstrated significant antitumor activity against solid tumors in various xenograft models and human clinical trials.
  • The antitumor potential of combining irofulven with 72 different anti-metabolite, enzyme inhibiting, and miscellaneous agents was investigated in this study.
  • Other anti-metabolites, enzyme inhibitors, and a variety of miscellaneous agents failed to interact beneficially when administered in combination with irofulven.
  • The therapeutic activity of irofulven is enhanced considerably when irofulven is combined with select anti-metabolite agents, and further clinical evaluation of these combinations is warranted.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors / administration & dosage. Fluorouracil / administration & dosage. Sesquiterpenes / administration & dosage
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Mice. Mice, Inbred BALB C. Random Allocation. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):1965-71 [9216653.001]
  • [Cites] Prostate. 2004 Apr 1;59(1):22-32 [14991863.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(2):133-43 [11883439.001]
  • [Cites] Invest New Drugs. 2006 Jul;24(4):311-9 [16683074.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1492-9 [14977853.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1191-6 [10568827.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):271-9 [12201490.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5604-13 [15328203.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):559-64 [12014623.001]
  • [Cites] Biochem Pharmacol. 1997 Dec 1;54(11):1181-93 [9416969.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):36-42 [15685033.001]
  • [Cites] J Am Chem Soc. 2007 Feb 21;129(7):2101-11 [17256933.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4936-40 [7585533.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 19;48(2):403-9 [8053936.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9 [16075278.001]
  • [Cites] J Nat Prod. 1996 Sep;59(9):896-9 [8864242.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26553-64 [11953432.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):55-61 [16260029.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1299-307 [10368691.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2499-504 [12171875.001]
  • [Cites] J Med Chem. 2006 Apr 20;49(8):2593-9 [16610802.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3377-85 [15161692.001]
  • [Cites] Cancer Invest. 1999;17(2):95-101 [10071592.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(3):235-40 [10453725.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):306-14 [10959900.001]
  • [Cites] Int J Cancer. 1987 Jul 15;40(1):46-52 [3596831.001]
  • [Cites] Pharmacol Rev. 1995 Jun;47(2):331-85 [7568331.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):278-84 [1998983.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4086-97 [11118470.001]
  • [Cites] Curr Biol. 2000 Apr 20;10(8):479-82 [10801416.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):867-71 [7645973.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4529-34 [10493501.001]
  • [Cites] Anticancer Drugs. 1996 May;7(3):339-43 [8792009.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1789-94 [11497260.001]
  • [Cites] Cancer Treat Rep. 1987 Mar;71(3):297-304 [3815395.001]
  • [Cites] Biochem Pharmacol. 2000 May 15;59(10):1217-26 [10736422.001]
  • [Cites] Surgery. 1999 May;125(5):536-44 [10330943.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):343-9 [15122083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1885-90 [10677551.001]
  • [Cites] J Biol Chem. 2004 Sep 17;279(38):39584-92 [15269203.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3186-9 [3472654.001]
  • [Cites] Biochem J. 2001 Nov 1;359(Pt 3):537-46 [11672427.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):279-83 [9000568.001]
  • [Cites] Blood. 1997 Jul 1;90(1):471 [9207485.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 1;58(11):1713-21 [10571245.001]
  • [Cites] Leukemia. 2000 Jan;14(1):136-41 [10637489.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5834-47 [12947390.001]
  • [Cites] Biochem Pharmacol. 2003 Feb 15;65(4):503-13 [12566077.001]
  • [Cites] Anticancer Drugs. 1999 Oct;10(9):837-44 [10587294.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 May;49(5):412-8 [11976836.001]
  • [Cites] Anticancer Drugs. 2000 Mar;11(3):217-24 [10831281.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2430-6 [11094320.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1049-53 [10070962.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Aug;126(8):461-7 [10961389.001]
  • [Cites] Biochem Pharmacol. 2007 Feb 15;73(4):469-80 [17118344.001]
  • [Cites] Invest New Drugs. 1996;14(2):161-7 [8913837.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):908-13 [9797706.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 May;55(5):411-9 [15503024.001]
  • [Cites] DNA Repair (Amst). 2002 Dec 5;1(12):1027-38 [12531012.001]
  • (PMID = 18227973.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Sesquiterpenes; 0W860991D6 / Deoxycytidine; 6B799IH05A / irofulven; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Ismail-Zade RS, Zhavrid EA, Aleĭnikova OV, Potapnev MP, Belevtsev MV, Isaĭkina IaI, Vashkevich EP, Savitskiĭ VP: [Use of LAK-cells and systemic chemotherapy with hyperthermia in the management of chemo-resistant tumors]. Vopr Onkol; 2010;56(6):681-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of LAK-cells and systemic chemotherapy with hyperthermia in the management of chemo-resistant tumors].
  • Tentative results of LAK-cell and whole-body hyperthermia (WBH) were evaluated in 19 children with advanced chemorefractory tumors.
  • LAK-cells were obtained by extracorporeal incubation of peripheral blood lymphocytes: a germ-cell rhabdomyosarcoma was detected in 4, Askin's tumor--2--2, renal cell carcinoma--2 and miscellaneous--7.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hyperthermia, Induced. Immunotherapy, Adoptive. Killer Cells, Lymphokine-Activated. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Body Temperature. Carcinoma, Renal Cell / therapy. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasms, Germ Cell and Embryonal / therapy. Neuroectodermal Tumors / therapy. Rhabdomyosarcoma, Embryonal / therapy. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21395124.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Weimin S, Gen Z, Guifu D, Yunxiao Z, Jin Z, Jingchao T: Synthesis and in vitro PDT activity of miscellaneous porphyrins with amino acid and uracil. Bioorg Med Chem; 2008 May 15;16(10):5665-71
Hazardous Substances Data Bank. COBALT, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and in vitro PDT activity of miscellaneous porphyrins with amino acid and uracil.
  • After reduction to the amino group and subsequent coupling with l-phenylalanine or 1-carboxylmethyl-5-fluorouracil (5-Fu acid), the functionalized porphyrins were metallized with Co(II) or Mn(II) to form miscellaneous porphyrins in good yields.
  • In vitro photodynamic therapy of the porphyrins against Ec9706 cell line was evaluated by standard cytotoxicity assays.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Organometallic Compounds / chemical synthesis. Organometallic Compounds / pharmacology. Phenylalanine / chemistry. Phloroglucinol / analogs & derivatives. Porphyrins / chemistry
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Cobalt / chemistry. Drug Screening Assays, Antitumor. Humans. Manganese / chemistry. Molecular Structure. Photochemistry. Photochemotherapy. Stereoisomerism. Structure-Activity Relationship. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439834.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Porphyrins; 0 / petiolin A; 3G0H8C9362 / Cobalt; 42Z2K6ZL8P / Manganese; 47E5O17Y3R / Phenylalanine; DHD7FFG6YS / Phloroglucinol
  •  go-up   go-down


7. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, Lacruz J, Valencia E, Santos J, Rodríguez-Arrondo F, Pintado V, Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas: Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr; 2007 Feb 1;44(2):167-73
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
  • OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).
  • RESULTS: During the study period, 210 consecutive patients were diagnosed with ARL, with a median age 39 of years, 75.7% of whom were male, and with a median baseline CD4 count of 160 cells/microL.
  • Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).
  • Chemotherapy with or without other modalities was administered to 186 (88.6%) patients.
  • In an intent-to-treat analysis of 184 patients who received at least 1 chemotherapy course with adequate follow-up to assess their response, 119 (64.7%) achieved CR, and the median length of survival (Kaplan-Meier analysis) was 52 months (95% confidence interval [CI]: 23 to 82 months).
  • CONCLUSIONS: In patients with ARL treated with HAART, CR was associated exclusively with tumor-related factors.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117144.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


8. Shepherd FA: Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. Semin Oncol; 2001 Apr;28(2 Suppl 4):30-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer.
  • Despite high initial response rates, most patients with small cell lung cancer (SCLC) relapse shortly after discontinuing therapy, and cure remains an elusive goal, even for patients with limited-stage disease.
  • For this reason, investigators have turned to the evaluation of alternative treatment strategies for patients with this malignancy.
  • Interferon has been evaluated in four trials of adjuvant therapy after response to chemotherapy for SCLC.
  • Tumor vaccines against gangliosides that are expressed on almost all human SCLC cells have been recently developed.
  • An anti-idiotypic monoclonal antibody against the GD3 ganglioside, BEC-2, is being evaluated after chemotherapy in SCLC patients in a European study.
  • Trials of anticoagulant therapy using heparin, warfarin, and aspirin were undertaken in the 1980s and early 1990s.
  • Although one study of warfarin and another of heparin showed trends in favor of anticoagulant therapy, there has been little research over the past decade evaluating this form of treatment of SCLC.
  • In all trials, the matrix metalloproteinase inhibitor is administered after chemotherapy and radiotherapy as adjuvant treatment.
  • Miscellaneous treatments, including monoclonal antibody therapy, tamoxifen, and growth factor inhibition have not yet been shown to have a role in the treatment of SCLC.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Anticoagulants / therapeutic use. Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Enzyme Inhibitors / therapeutic use. Humans. Immunotherapy. Interferons / therapeutic use. Matrix Metalloproteinase Inhibitors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11479895.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 9008-11-1 / Interferons
  • [Number-of-references] 50
  •  go-up   go-down


9. Konovalov AN, Pitskhelauri DI: Principles of treatment of the pineal region tumors. Surg Neurol; 2003 Apr;59(4):250-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of treatment of the pineal region tumors.
  • BACKGROUND: A pineal region tumor is an uncommon deep-seated, heterogeneous group of mass lesions of the brain, and the management strategy of any types of these tumors remains controversial.
  • METHODS: From 1976 to 1999 about 700 patients with tumors of the pineal region and posterior third ventricle were managed at the Burdenko Neurosurgery Institute.
  • In more than 330 cases the tumor was removed.
  • In this paper we present results of 287 patients with histologically verified pineal region tumors for the period from 1976 to 1999.
  • All of them had verified tumor histology, excluding only five cases in which stereotactic biopsy procedures were uninformative.
  • There are four main groups of tumors: the germ cell tumors-87 (31%); the pineal parenchymal tumors-75 (27%); the glial tumors-77 (27%); and miscellaneous-43 (15%).
  • There were 255 surgical procedures for tumor removal performed in 244 and stereotactically guided biopsies in 61 patients, 168 (58%) with obstructive hydrocephalus who underwent cerebrospinal fluid shunting.
  • Radiation therapy was administered in 145 (51%) and chemotherapy in 16 patients.
  • A total tumor removal was achieved in 148 operations (58%), subtotal in 74 (29%) and partial in 33 (13%).
  • The projected 5-year and 10-year survival rates for patients with malignant pineal tumors, who received irradiation after tumor resection or underwent radiation therapy alone, were: 95% and 88% for pure germinomas, 80% and 50% for high grade gliomas, 44% and 0% for malignant pineal parenchymal tumors, and 20% and 0% for malignant germ cell tumors, respectively.
  • CONCLUSIONS: Benign pineal tumors should be cured with surgery alone.
  • Malignant tumors should be treated with aggressive resection followed with irradiation and chemotherapy.
  • Pure germinomas, which are exquisitely radiosensitive, can be cured by conventional radiation therapy alone.
  • [MeSH-minor] Adolescent. Adult. Animals. Biopsy. Child. Child, Preschool. Female. Humans. Hydrocephalus / etiology. Male. Middle Aged. Prognosis. Retrospective Studies. Stereotaxic Techniques. Survival. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12748006.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Suffredini IB, Varella AD, Younes RN: Cytotoxic molecules from natural sources: tapping the Brazilian biodiversity. Anticancer Agents Med Chem; 2006 Jul;6(4):367-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of plant miscellaneous preparations as an alternative to the treatment of cancer is a reality today due to the massive marketing of natural medicines versus anticancer chemotherapy.
  • Although this situation is controversial and has not led to any significant benefits to patients, plants may play a significant role in the treatment of cancer.
  • Natural products are still some of the important sources of new anticancer drugs.
  • The Brazilian flora is considered one of the most diverse in the world, although not many large-scale pharmacological and phytochemical studies have been conducted so far.
  • We present the updated status and results of the research developed by Brazilian research centers on anticancer active substances derived from natural sources, mainly plants from the Brazilian Rain Forests, focusing on their potential effectiveness and difficulties.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Plant Preparations / therapeutic use
  • [MeSH-minor] Brazil. Cell Line, Tumor / metabolism. Drug Screening Assays, Antitumor / methods. Humans. Phytotherapy

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842236.001).
  • [ISSN] 1871-5206
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Preparations
  • [Number-of-references] 48
  •  go-up   go-down


11. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C: Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol; 2003 Nov;4(11):670-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic diseases (GTD) consist of a group of neoplastic disorders arising from placental trophoblastic tissue after normal or abnormal fertilisation.
  • The WHO classification of GTD includes hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour, and miscellaneous and unclassified trophoblastic lesions.
  • GTD have a varying potential for local invasion and metastases and they generally respond to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14602247.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


12. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R: Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol; 2001 Jun-Jul;23(5):277-81
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
  • PURPOSE: To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors.
  • PATIENTS AND METHODS: Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330).
  • Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12).
  • All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease.
  • All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial.
  • Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity.
  • RESULTS: Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy.
  • CONCLUSION: Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Child, Preschool. Dexamethasone / therapeutic use. Disease Progression. Drug Hypersensitivity / prevention & control. Ependymoma / drug therapy. Ependymoma / pathology. Female. Glioma / drug therapy. Glioma / pathology. Humans. Immunosuppressive Agents / therapeutic use. Infant. Infratentorial Neoplasms / drug therapy. Infratentorial Neoplasms / pathology. Infusions, Intravenous. Male. Medulloblastoma / drug therapy. Medulloblastoma / pathology. Nausea / chemically induced. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Remission Induction. Salvage Therapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464982.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA07431; United States / NCI NIH HHS / CA / CA15525; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Immunosuppressive Agents; 7S5I7G3JQL / Dexamethasone; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Kurbacher CM, Schmidt M, Kurbacher JA, Schäfer S, Arenz PN, Nagel WJ, Reinhold U: Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):e14544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial.
  • : e14544 Background: BEV is potent inhibitor of VEGF-mediated tumor angiogenesis.
  • METHODS: 26 pts have been enrolled: epithelial ovarian cancer, n=12; breast cancer, n= 6; primary peritoneal carcinoma, n=3; hormone-refractory prostate cancer, n=2; miscellaneous, n=3.
  • All pts have been considered refractory to or non-treatable by chemotherapy due to their baseline bone marrow and/or organ functions.
  • The median time to progression is 92 days and the median overall survival is 302 days.
  • CONCLUSIONS: BEV+GM-CSF is an active and generally well tolerated non-cytotoxic regimen in pts with advanced solid tumors.
  • Thus, large-scaled studies of this promising treatment are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963617.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gourley M, Williamson JS: Angiogenesis: new targets for the development of anticancer chemotherapies. Curr Pharm Des; 2000 Mar;6(4):417-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To ensure an adequate blood supply, tumor cells release angiogenic factors that are capable of promoting nearby blood vessels to extend vascular branches to the tumor.
  • In addition, larger tumors have been shown to release angiogeneic inhibitory factors that prevent blood vessels from sending branches to smaller, more distant tumors that compete for oxygen and nutrients.
  • Angiogenesis is a complex multistep biochemical process, and offers several potential molecular targets for non-cytotoxic anticancer therapies.
  • Strategies for exploiting tumor angiogenesis for novel cancer drug discovery include: (i) inhibition of proteolytic enzymes that breakdown the extracellular matrix surrounding existing capillaries;.
  • (iv) enhancement of tumor endothelial cell apoptosis.
  • There is also a host of miscellaneous agents that inhibit angiogenesis for which the specific mechanisms are not clear.
  • Several methods have been developed for measuring antiangiogenic activity both in vitro and in vivo.
  • Although there has been intensive research efforts focused at the phenomena of angiogenesis, as well as the search for antiangiogenic agents for more than two decades, many questions remain unanswered with regard to the overall biochemical mechanisms of the angiogenesis process and the potential therapeutic utility of angiogenic inhibitors.
  • Nevertheless potent angiogenic inhibitors capable of blocking tumor growth have been discovered, and appear to have potential for development into novel anticancer therapeutics.
  • However there are still hurdles to be overcome before these inhibitors become mainstream therapies.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / pharmacology. Neoplasms / drug therapy. Neoplasms / pathology. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Animals. Humans. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10788590.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 120
  •  go-up   go-down


15. Kanayama M, Hashimoto T, Shigenobu K, Oha F, Togawa D: Effective prevention of surgical site infection using a Centers for Disease Control and Prevention guideline-based antimicrobial prophylaxis in lumbar spine surgery. J Neurosurg Spine; 2007 Apr;6(4):327-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathophysiologies among these patients included disc herniation in 686, degenerative spondylolisthesis in 340, spinal stenosis in 259, failed lumbar surgeries in 73, degenerative scoliosis in 52, isthmic spondylolisthesis in 48, spinal trauma in 34, foraminal stenosis in 27, spinal tumor in 27, and miscellaneous in 51 patients.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Centers for Disease Control and Prevention (U.S.) / standards. Practice Guidelines as Topic. Spinal Diseases / surgery. Surgical Wound Infection / drug therapy. Surgical Wound Infection / prevention & control
  • [MeSH-minor] Drug Resistance, Bacterial. Humans. Infection Control / methods. Intervertebral Disc Displacement / epidemiology. Intervertebral Disc Displacement / surgery. Lumbar Vertebrae. Reoperation / statistics & numerical data. Scoliosis / epidemiology. Scoliosis / surgery. Spinal Neoplasms / epidemiology. Spinal Neoplasms / surgery. Spinal Stenosis / epidemiology. Spinal Stenosis / surgery. Spondylolisthesis / epidemiology. Spondylolisthesis / surgery. United States

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436921.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


16. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • The most important is obviously the precursor lesion of germ cell tumors, which has been called "intratubular malignant germ cells".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This lesion is missed in germ cell tumors of childhood and in spermatocytic seminomas, both seem to have a histogenetic history rather different from the other germ cell in adults.
  • Most of the new diagnoses are subtypes--called "variants"--of well known tumors.
  • Spermatocytic seminomas are perfectly benign tumors but they become a life threatening disease when combined with sarcomas (new entity).
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • In contrast to gonadoblastoma, however, these tumors occur in testes of genotypic and phenotypic normal males.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


17. Mulne AF, Ducore JM, Elterman RD, Friedman HS, Krischer JP, Kun LE, Shuster JJ, Kadota RP: Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol; 2000 Jan-Feb;22(1):41-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.
  • PURPOSE: Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis.
  • Patients in six different brain tumor strata were accrued.
  • RESULTS: The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12.
  • CONCLUSION: Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types.
  • This regimen will not be recommended for front-line therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / drug therapy. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10695820.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-03161; United States / NCI NIH HHS / CA / CA-29691; United States / NCI NIH HHS / CA / CA-69177; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Orditura M, De Vita F, Galizia G, Lieto E, Vecchione L, Vitiello F, Martinelli E, Ciardiello F: Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep; 2009 Apr;21(4):1023-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
  • We retrospectively analyzed 90 cetuximab-treated patients: 57 colon cancer patients, 10 NSCLC patients, 14 locally advanced esophageal cancer patients, and 9 miscellaneous.
  • A significant correlation was observed between skin rash and response to therapy.
  • Patients who did not develop skin rash had a 2-fold greater likelihood to manifest tumor progression significantly earlier than patients who developed skin rash.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Exanthema / chemically induced. Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Rashes.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288004.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


19. Cacheux W, Gourmel B, Alexandre J, Germann N, Rabillon F, Duffau B, Goldwasser F: An original administration of ifosfamide given once every other week: a clinical and pharmacological study. Anticancer Drugs; 2008 Mar;19(3):295-302
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
  • Ifosfamide (IFOS) is a bifunctional alkylator with a wide spectrum of activity in solid tumors and has an autoinductive liver metabolism through P450 cytochromes.
  • Autoinduction might permit a better therapeutic index for combination therapy.
  • A phase I trial was investigated with interpatient dose escalation of a single dose of IFOS given every 2 weeks in advanced solid tumor patients.
  • The primary tumor was most often ovarian (5), peritoneal (3), sarcoma (2), melanoma (2) or miscellaneous (8).
  • The toxicity profile allows the development of bi-weekly IFOS-based combination therapies.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Ifosfamide / administration & dosage. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Area Under Curve. Chromatography, Gas. Cytochrome P-450 Enzyme System / drug effects. Dose-Response Relationship, Drug. Enzyme Induction / drug effects. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510176.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 9035-51-2 / Cytochrome P-450 Enzyme System; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


20. Levi AW, Potter SR, Schoenberg MP, Epstein JI: Clinical significance of denuded urothelium in bladder biopsy. J Urol; 2001 Aug;166(2):457-60
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We correlated the pertinent clinical features of patients with denuded bladder biopsies and/or specific pathological features of denuded bladder biopsy specimens with patient outcome in regard to bladder lesions to help predict the subsequent likelihood of diagnosing bladder carcinoma in a patient with a nondiagnostic denuded biopsy.
  • In remainder there were flat carcinoma in situ with or without other tumors (26%), high (20%) and low (14%) grade papillary tumors without carcinoma in situ and miscellaneous conditions (6%).
  • Parameters that did not correlate with the subsequent diagnosis of carcinoma in situ included cystoscopic impression, history of intravesical chemotherapy, sex, age, tissue inflammation, percent of tissue fragments with any denudation, number of denuded tissue fragments and percent of overall denuded epithelium.
  • Factoring in a history of other bladder tumor types in various combinations did not predict carcinoma in situ after denuded biopsy.
  • Carcinoma in situ developed within 24 months in 45% of patients in whom the denuded specimen was obtained by cold cup biopsy in contrast to none who underwent hot wire loop biopsy (p = 0.007).
  • Carcinoma in situ developed within 24 months in 75% of patients with a history of that condition and a subsequent cold cup biopsy showing denuded epithelium.
  • When the denuded biopsy sample was obtained by cold cup biopsy, particularly when associated with a history of carcinoma in situ, most cases represent neoplastic cell denudation and a high risk for subsequent carcinoma in situ.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458047.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement